Search the Newsreel

BioRestorative Therapies Inc expected to post a loss of 12 cents a share - Earnings Preview

BioRestorative Therapies Inc (BRTX) is anticipated to report an earnings loss of 12 cents per share. This information comes from a Refinitiv earnings preview. The full article, originally from Reuters, is available on TradingView.

BioRestorative Therapies Inc (BRTX) Stock News Today

This article provides current stock information for BioRestorative Therapies Inc (BRTX), including its latest stock price, market capitalization, and a note that more news is coming soon. It serves as a placeholder for financial news and analyst ratings related to the company. The page …

BioRestorative Therapies Inc (BRTX) Earnings Forecast: Future EPS & Revenue Growth Estimates

BioRestorative Therapies (BRTX) investor Alta Partners reports 4.99% ownership cap

Alta Partners LLC has filed an amended Schedule 13G, reporting beneficial ownership of 1,338,133 shares of BioRestorative Therapies, Inc. common stock, which represents 4.99% of the class. This percentage is capped due to a beneficial ownership limitation in an applicable warrant. Steven Cohen, Managing …

BioRestorative Therapies (BRTX) reports director Esha Randhawa’s insider status

BioRestorative Therapies, Inc. (BRTX) has filed an initial statement of beneficial ownership for its director, Esha Randhawa, indicating her insider status. The report, a Form 3, shows no reported transactions, share purchases, sales, or derivative positions for Randhawa. This signifies an initial disclosure of …

BioRestorative Therapies Inc (BRTX) Valuation: PE, PB & Fair Value Analysis

BioRestorative Therapies Inc (BRTX) currently holds a valuation score of 7.70, placing it 153rd out of 385 companies in the Biotechnology & Medical Research industry. The company's P/E ratio is -0.19, which is significantly below its recent high and above its recent low. However, …

BioRestorative Therapies, Inc. Revenue Breakdown – DUS:9OF

This article provides a revenue breakdown for BioRestorative Therapies, Inc. (DUS:9OF). In the last year, the company generated 306.51K EUR, primarily from its Therapeutic Products and Medical Therapies segment (306.26K EUR), with the majority of revenue originating from the United States.

BioRestorative Therapies Inc

This article for BioRestorative Therapies Inc (BRTX) from TradingKey primarily focuses on the company's revenue breakdown. It indicates that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The page also provides basic stock information, …

BioRestorative Therapies Inc (BRTX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of BioRestorative Therapies Inc (BRTX) regarding its dividend and stock split history. It notes that the company has distributed $0.00 in dividends over the past five years. The page displays current stock information including its market capitalization but shows …

BRTX|BioRestorative Therapies Inc|Price:0.290|Chg%:-0.022

BioRestorative Therapies Inc. (BRTX) is a company focused on developing therapeutic products using adult stem cells, with key programs targeting disc/spine disease and metabolic disorders. Its lead candidate, BRTX-100, is in a Phase II clinical trial for chronic lower back pain. The company also …

BioRestorative Therapies, Inc. Revenue Breakdown – GETTEX:9OF

This article details the revenue breakdown for BioRestorative Therapies, Inc. (Gettx:9OF), highlighting that in the last year, the company generated 306.51K EUR, primarily from its Therapeutic Products and Medical Therapies segment. The United States was the greatest contributor to this revenue.

BioRestorative Therapies (BRTX) Q1 2026 Earnings: Narrower Loss Beats Estimates as Company Advances Pipeline - Annual Financial Report

Leadership shake-up at Biorestorative Therapies (NASDAQ: BRTX) and new CEO

BioRestorative Therapies (BRTX) has undergone a significant leadership change, with President, CEO, and Chairman Lance Alstodt and CFO Robert Kristal resigning, claiming "Good Reason" due to an alleged Change in Control and seeking approximately $2.85 million in severance, which the board disputes. Director Katharyn …

BioRestorative Therapies, Inc. Announces CFO Changes, Effective July 13, 2026

BioRestorative Therapies, Inc. announced the resignation of CFO Robert Kristal, effective July 13, 2026, citing "Good Reason" due to a Change in Control related to Board changes in June 2026. The Board disputes the validity of the claims and has initiated an investigation into …

BRTX Q1 2026 Earnings: EPS Beat Drives Stock Higher Despite No Revenue - EBITDA Estimate Trend

BRTX Q1 2026 Earnings: Narrowed Loss Per Share Beats Estimates, Stock Rises - Dividend Growth Analysis

BRTX Q1 2026 Earnings: EPS Surprises with Wider-Than-Expected Beat as Pipeline Advances - One-Time Loss Impact

BioRestorative Therapies Inc. (BRTX) Q1 2026 Earnings: Narrowing Losses Drive Strong Stock Surge - Book Value Growth

What Makes Biorestorative Therapies (BRTX) a New Buy Stock

Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Misses Revenue Estimates

Here's Why Biorestorative Therapies (BRTX) Looks Ripe for Bottom Fishing

Biorestorative Therapies, Inc. (BRTX) Reports Q4 Loss, Lags Revenue Estimates

BIORESTORATIVE THERAPIES ($BRTX) Releases Q4 2025 Earnings, Stock Rises | BRTX Stock News

BioRestorative Therapies, Inc.'s (NASDAQ:BRTX) Profit Outlook

Biorestorative Therapies (BRTX) Stock Price, News & Analysis

BioRestorative Therapies Inc (BRTX) Earnings, Actual EPS, EPS Estimates & Results

What date does Biorestorative Therapies's (BRTX) report Earnings - Earnings Calendar & Announcement

BioRestorative Therapies, Inc. (BRTX) stock price, news, quote and history

Should I buy Biorestorative Therapies (BRTX)